Press Releases

The following are official statements issued by UsAgainstAlzheimer’s in response to major national policy actions, industry events, breaking news, or organizational achievements. Please see the UsAgainstAlzheimer’s press kit page for additional information. For media requests, please contact Jon Summers at jsummers@usagainstalzheimers.org.

  • December 01, 2022

    Gantenerumab Trial Results Reinforce Need for Continued Research and Treatment-Specific Regulation

    Yesterday, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, researchers ...

    Read more
  • November 30, 2022

    Lecanemab Trial Data Gives Hope to Alzheimer’s Community

    Washington, DC (November 29, 2022) – Promising new data released today...

    Read more
  • November 21, 2022

    Faith in Action Campaign Launches to Promote Brain Health Among Black Americans

    Faith in Action Campaign Launches to Promote Brain Health Among Black American

    Read more
  • November 15, 2022

    Treatment Momentum Must Continue Despite Disappointing Trial Data

    Significant progress continues to be made in the effort to treat people...

    Read more
  • October 20, 2022

    Sen. Collins, Rep. Eshoo Decry Medicare Coverage Rejection of Alzheimer’s Drugs

    During UsAgainstAlzheimer’s 2022 National Summit, members of Congress, scientists, and other...

    Read more
  • October 05, 2022

    New Bipartisan Bill would Prevent CMS from Denying Coverage for Entire Classes of Drugs

    Following the unconscionable and historic decision by the Centers for Medicare and...

    Read more
  • September 28, 2022

    Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

    Alzheimer’s patients and their loved ones have new reason for hope following...

    Read more
  • September 27, 2022

    Months After Denying Medicare Coverage for Alzheimer’s Drugs, CMS Announces a Premium Cut

    The Centers for Medicare and Medicaid Services (CMS) has announced it plans...

    Read more
  • August 08, 2022

    FDA Deals Major Blow to Patients with Alzheimer’s-Related Psychosis

    Yesterday, Acadia Pharmaceuticals announced that it has been told by the FDA...

    Read more

Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer's. This report found that deep social inequities exist in countries highly impacted by Alzheimer's among Latinos and Blacks.